JR Rahn is stepping down as MindMed’s CEO, to be replaced by Chief Development Officer, Robert Barrow.

Field Trip Health has uplisted to the TSX in Canada.

Psilocybin, the active compound in magic mushrooms, may be at least as effective as selective serotonin reuptake inhibitors, the leading type of antidepressant medication, according to research published in the New England Journal of Medicine.

Investors are always looking for hot new markets to invest in.

Oregon’s move to legalize psilocybin mushrooms for therapeutic use should signal to the federal government that it needs to engage with jurisdictions that pursue such reforms and aid in the development of regulatory frameworks, a federal health official says.

A Northeast Sustainable Cannabis Project representative told lawmakers on Tuesday that the Massachusetts cannabis industry is responsible for 10% of all industrial electricity use in the state and urged them to allow industry cultivators to use organic farming and outdoor technics, according to a MassLive report.

A Psychedelic Drug Revolution is underway to address the Mental Health Crisis. As with all revolutions, we are seeing a rapid shift in attitudes.

Hallucinogens benefit from somewhat greater acceptance than many other hard drugs, no doubt due in part to the fact that classic hallucinogens like LSD tend to be less harmful and are less likely to lead to physical dependence.

Novamind’s clinic revenues jumped 43% quarter-over-quarter, to CAD$1.85 million. Projecting a 225% increase in clinic visits year-over-year.

A New York lawmaker introduced a bill on Tuesday that would require the state to establish an institute to research the therapeutic potential of psychedelics.